492 related articles for article (PubMed ID: 31566449)
1. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
[No Abstract] [Full Text] [Related]
2. Interstitial lung disease associated with systemic sclerosis (SSc-ILD).
Cottin V; Brown KK
Respir Res; 2019 Jan; 20(1):13. PubMed ID: 30658650
[TBL] [Abstract][Full Text] [Related]
3. Management of systemic sclerosis-associated interstitial lung disease.
Roofeh D; Jaafar S; Vummidi D; Khanna D
Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
5. Scleroderma-related interstitial lung disease: principles of management.
Das A; Kumar A; Arrossi AV; Ghosh S; Highland KB
Expert Rev Respir Med; 2019 Apr; 13(4):357-367. PubMed ID: 30686069
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of systemic sclerosis-associated interstitial lung disease].
Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
[TBL] [Abstract][Full Text] [Related]
7. Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.
Mackintosh JA; Stainer A; Barnett JL; Renzoni EA
Semin Respir Crit Care Med; 2019 Apr; 40(2):208-226. PubMed ID: 31137061
[TBL] [Abstract][Full Text] [Related]
8. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
11. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
[TBL] [Abstract][Full Text] [Related]
12. Treatment for systemic sclerosis-associated interstitial lung disease.
Roofeh D; Lescoat A; Khanna D
Curr Opin Rheumatol; 2021 May; 33(3):240-248. PubMed ID: 33741803
[TBL] [Abstract][Full Text] [Related]
13. Interstitial Lung Disease Associated with Systemic Sclerosis.
Mismetti V; Si-Mohamed S; Cottin V
Semin Respir Crit Care Med; 2024 Jun; 45(3):342-364. PubMed ID: 38714203
[TBL] [Abstract][Full Text] [Related]
14. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Volkmann ER; Tashkin DP
Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological management of systemic sclerosis associated interstitial lung disease.
Dixon G; Adamali I; Adamali H; Barratt S; Gunarwardena H; Pauling JD
Expert Opin Pharmacother; 2023 May; 24(7):815-824. PubMed ID: 37029594
[TBL] [Abstract][Full Text] [Related]
18. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.
Silver KC; Silver RM
Rheum Dis Clin North Am; 2015 Aug; 41(3):439-57. PubMed ID: 26210128
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all.
Spierings J; Chiu YH; Voortman M; van Laar JM
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211035196. PubMed ID: 34394749
[TBL] [Abstract][Full Text] [Related]
20. Management of systemic sclerosis: the first five years.
Roofeh D; Khanna D
Curr Opin Rheumatol; 2020 May; 32(3):228-237. PubMed ID: 32205570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
